The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

Share Price Information for Belluscura (BELL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.00
Bid: 7.50
Ask: 8.50
Change: 0.00 (0.00%)
Spread: 1.00 (13.333%)
Open: 8.00
High: 8.00
Low: 8.00
Prev. Close: 8.00
BELL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

5 Feb 2024 13:30

RNS Number : 0613C
Belluscura PLC
05 February 2024

5 February 2024

BELLUSCURA PLC

("Belluscura" or the "Company")

Recommended all-share offer for TMT Acquisition plc by Belluscura plc

Rule 9 Waiver

Result of General Meeting

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that at the General Meeting held earlier today the sole ordinary resolution put to the meeting by way of a poll was duly approved by those Shareholders eligible to vote:

Votes for

% of shares voted

Votes against

% of shares voted

Total votes (including withheld)

% of issued share capital voted by Independent Shareholders eligible to vote

Votes withheld by Independent Shareholders eligible to vote

Rule 9 Waiver Resolution

68,061,701

99.94%

38,605

0.06%

68,112,221

74.19%

11,915

Notes:

1. The full text of the Rule 9 Waiver Resolution is set out in the Notice of the General Meeting, which can be found at Part III of the Circular.

2. Any proxy appointments which gave discretion to the Chairman have been included in the 'for' total.

3. A 'Vote withheld' is not counted towards the votes 'for' or 'against' the Rule 9 Waiver Resolution.

4. The total number of Ordinary Shares in issue on 1 February 2024 was 137,532,567.

5. Total Ordinary Shares held by the Independent Shareholders on 1 February 2024 was 91,738,961.

6. Total Ordinary Shares held by the Belluscura Concert Party on 1 February 2024 was 45,748,606.

7. In accordance with the terms of the waiver of Rule 9 of the Code granted by the Panel, only Independent Shareholders were permitted to vote on the Rule 9 Waiver Resolution.

As a result, the waiver of a potential obligation under Rule 9 of the Takeover Code for the Belluscura Concert Party to make a mandatory general cash offer for the whole of the issued and to be issued share capital of Belluscura not already owned by the Belluscura Concert Party has been approved. Accordingly, this condition of the Offer has been satisfied.

Terms used but not defined in this announcement have the same meaning as set out in the Circular to Shareholders published by Belluscura on 19 January 2024.

For further information please contact:

Belluscura plc

via MHP Group

Adam Reynolds, Chairman

Robert Rauker, Chief Executive Officer

Simon Neicheril, Chief Financial Officer

SPARK Advisory Partners Limited (Nominated Advisor)

Tel: +44 (0)20 3368 3554

Neil Baldwin / Jade Bayat

Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715

Russell Cook / Nicholas Chambers

MHP (Financial PR & Investor Relations)

Tel: +44 (0)20 3128 8100

Katie Hunt / Matthew Taylor

belluscura@mhpgroup.com

Responsibility

The persons responsible for the contents of this announcement are the Belluscura Directors.

Disclosure requirements of the Code

Under Rule 8.3(a) of the Takeover Code, any person who is directly or indirectly interested in one per cent. or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the Offer Period and, if later, following the announcement in which any securities exchange offeror is first identified.

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. (London time) on the 10th Business Day following the commencement of the Offer Period and, if appropriate, by no later than 3.30 p.m. (London time) on the 10th Business Day following the announcement in which any securities exchange offeror is first identified.

Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure. Under Rule 8.3(b) of the Takeover Code, any person who is, or becomes, interested in one per cent. or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. (London time) on the Business Day following the date of the relevant dealing. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4). Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at www.thetakeoverpanel.org.uk , including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 20 7638 0129 if you are in any doubt as to whether you are required to make an or a Dealing Disclosure.

Important notice related to financial advisors

SPARK Advisory Partners, which is authorised and regulated by the FCA in the UK, is acting as nominated adviser exclusively for Belluscura and no one else in connection with the Offer and this announcement and will not be responsible to anyone other than Belluscura for providing the protections afforded to clients of SPARK Advisory Partners or for providing advice in relation to the Offer the content of this announcement or any matter referred to herein.

Dowgate Capital, which is authorised and regulated by the FCA in the UK, is acting as financial adviser and broker exclusively for Belluscura and no one else in connection with the Offer and this announcement and will not be responsible to anyone other than Belluscura for providing the protections afforded to clients of Dowgate Capital or for providing advice in relation to the Offer the content of this announcement or any matter referred to herein.

Overseas Shareholders

The Offer relates to securities in a company which is registered in England and Wales, which is admitted to trading on AIM and is subject to the disclosure requirements, rules and practices applicable to such companies, which differ from those of Restricted Jurisdictions in certain material respects. This announcement has been prepared for the purposes of complying with English law, the AIM Rules for Companies, the Market Abuse Regulation, the rules of London Stock Exchange and the Code, and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws of jurisdictions outside the United Kingdom. The release, publication or distribution of this announcement in or into certain jurisdictions other than the United Kingdom may be restricted by law and therefore any persons who are subject to the laws of any jurisdiction other than the United Kingdom should inform themselves about, and observe, any applicable requirements. To the fullest extent permitted by applicable law, the companies and persons involved in the Offer disclaim any responsibility or liability for the violation of such restrictions by any person.

Copies of this announcement and formal documentation relating to the Offer shall not be, and must not be, mailed or otherwise forwarded, distributed or sent in, into or from the United States or any other Restricted Jurisdiction or any jurisdiction where to do so would violate the laws of that jurisdiction and persons receiving such documents (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send them in, into or from the United States or any other Restricted Jurisdiction. Doing so may render invalid any related purported acceptance of the Offer. Unless otherwise determined by the Code and permitted by applicable law and regulation, the Offer may not be made, directly or indirectly, in or into, or by the use of mails or any means or instrumentality (including, but not limited to, e-mail or other electronic transmission, telex or telephone) of interstate or foreign commerce of, or of any facility of a national, state or other securities exchange of the United States or any other Restricted Jurisdiction and the Offer may not be capable of acceptance by any such use, means, instrumentality or facilities or otherwise from within the United States or any other Restricted Jurisdiction. Accordingly, copies of this announcement, the Offer Document, the Form of Acceptance and all other accompanying documents relating to the Offer are not being, and must not be directly or indirectly, mailed or otherwise distributed or sent in, into or from the United States or any other Restricted Jurisdiction.

Persons receiving this announcement, Offer Document, the Form of Acceptance and all other accompanying documents relating to the Offer (including, without limitation, custodians, nominees and trustees) should observe these restrictions and must not mail, otherwise forward, send, or distribute them in, into or from the United States or any other Restricted Jurisdiction or use such mails or any such means, instrumentality or facility for any purpose directly or indirectly in connection with the Offer, and doing so may render invalid any related purported acceptance of the Offer.

Further details in relation to Overseas Shareholders are contained in the Offer Document.

Publication on Website

In accordance with Rule 26.1 of the Code, a copy of this announcement will be available on the investor section of Belluscura's website at https://ir.belluscura.com by no later than 12.00 noon (London time) on the Business Day immediately following the date of this announcement. The content of the websites referred to in this announcement is not incorporated into and does not form part of this announcement.

Availability of Hard Copies

Pursuant to Rule 30.3 of the Code, a person so entitled may request a copy of this announcement and any information incorporated into it by reference to another source in hard copy form by writing to Link Group Corporate Actions, Central Square, 29 Wellington Street, Leeds, LS1 4DL, United Kingdom. A person may also request that all future documents, announcements and information to be sent to that person in relation to the Offer should be in hard copy form.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ROMEADASEAKLEFA
Date   Source Headline
10th Oct 20234:19 pmRNSForm 8.3 - TMT Acquisition PLC
10th Oct 20233:54 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:52 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:47 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:45 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:45 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:42 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:28 pmGNWForm 8.3 - Belluscura PLC
9th Oct 20236:11 pmRNSForm 8.3 - Belluscura Plc
9th Oct 20232:32 pmRNSForm 8.3 - Belluscura PLC
9th Oct 20231:39 pmRNSRule 2.9 Announcement
9th Oct 20238:10 amRNSRule 2.9 Announcement
6th Oct 202312:48 pmRNSConditional Allotment and Issue of Placing
5th Oct 20234:49 pmRNSForm 8.3 - Belluscura PLC
3rd Oct 20236:28 pmRNSReplacement - Placing of Unsecured CLNs
3rd Oct 20231:53 pmRNSDirectorate Change
3rd Oct 20231:38 pmRNSPlacing of Unsecured Convertible Loan Notes
3rd Oct 20231:30 pmRNSStatement re Possible Offer
3rd Oct 20231:30 pmRNSStatement regarding possible offer
26th Sep 20237:00 amRNSBelluscura Receives Approval in Hong Kong
14th Sep 20234:26 pmRNSResult of AGM
13th Sep 20237:00 amRNSHalf-year Report
30th Aug 20237:00 amRNSBelluscura Enters Exclusive License Agreement
16th Aug 20237:00 amRNSOrders for over 6,500 DISCOV-R™ received
1st Aug 20237:00 amRNSBelluscura Signs Distribution Agreement
12th Jul 20237:00 amRNSNotice of AGM and Annual Report 2022
29th Jun 20237:00 amRNSBelluscura Commences Premarket Launch of DISCOV-R™
29th Jun 20237:00 amRNSFinal Results for the year ended 31 December 2022
15th Jun 20237:00 amRNSShare allotment; Director/PDMR Shareholding; Appt.
14th Jun 202312:28 pmRNSResult of General Meeting
1st Jun 20237:00 amRNSResult of Retail Offer
26th May 20237:00 amRNSProposed Board Appointment
25th May 202311:15 amRNSRetail Offer to raise up to £0.5m
25th May 202311:00 amRNSProposed Placing and Subscriptions to raise £3.0m
28th Apr 20237:00 amRNSAdditional Broker Option - Extension
20th Apr 20238:19 amRNSExercise of Warrants and Total Voting Rights
3rd Apr 20237:00 amRNSBelluscura begins manufacturing in China
30th Mar 20237:00 amRNSChange of Auditor
24th Feb 20237:00 amRNSBelluscura POC now marketed through GoodRx®
16th Feb 202311:59 amRNSResult of General Meeting
10th Feb 20237:00 amRNSResult of Broker Option
31st Jan 20233:41 pmRNSPosting of Circular
27th Jan 20232:00 pmRNSPrice Monitoring Extension
27th Jan 202312:41 pmRNSPlacing of Unsecured Convertible Loan Notes
24th Jan 20234:40 pmRNSSecond Price Monitoring Extn
24th Jan 20234:35 pmRNSPrice Monitoring Extension
16th Jan 20237:00 amRNSBelluscura appoints Senior VP of Global Sales
13th Jan 20237:00 amRNSYear-end Trading Update
11th Jan 20234:40 pmRNSSecond Price Monitoring Extn
11th Jan 20234:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.